Abstract
Objective. To assess the association of age, anaemia, impaired renal function and concomitant therapy with direct oral anticoagulant (DOAC)-related outcomes in patients aged 60 years and older with multimorbidity and polypharmacy.
Material and methods. This prospective single-centre study included 503 patients aged 60 years and older receiving DOACs for non-valvular atrial fibrillation in the geriatric, internal medicine and cardiology departments of Moscow War Veterans Hospital No.2 from April 2023 to September 2024. Polypharmacy was defined as the concomitant use of five or more medications. Treatment interruption, haemorrhagic complications, DOAC switching, and a composite measure of uninterrupted treatment without recorded complications were assessed.
Results. Treatment interruption was more frequent in patients aged 70 years and older than in those younger than 70 years (42.0% vs 18.5%; p=0.009). Patients with creatinine clearance
Keywords
Authors and affiliations
https://elibrary.ru/odmlra A.P. Kondrakhin(1–3), T.R. Kameneva(4), E.G. Silina(5), M.L. Maksimov(1, 6, 7), M.V. Zhuravleva(8, 9),
E.M. Nigmatullina(1), S.A. Martynova(1), Yu.S. Bondareva(1), E.A. Begichev(10), S.V. Nagornyak(9)
1-Federal State Autonomous Educational Institution of Higher Education “Russian National Research Medical University named after N.I. Pirogov”
of the Ministry of Health of the Russian Federation, Ostrovityanova str., 1, Moscow, 117997, Russian Federation; 2-Moscow State Budgetary Healthcare Institution “Hospital for War Veterans No.2 of the Moscow City Healthcare Department”, Volgogradskiy Prospekt, 168, Moscow, 109472, Russian Federation; 3-Moscow Region State Budgetary Healthcare Institution “L.M. Roshal Children’s Clinical Center”, Children’s Clinical Center Territory, build. 1, Krasnogorsk Urban District, Moscow Region, 143402, Russian Federation; 4-State Budgetary Institution of Moscow City “Scientific Research Institute of Healthcare Organization and Medical Management of Moscow City Healthcare Department”, Sharikopodshipnikovskaya, Street, 9, Moscow, 115088, Russian Federation; 5-Federal State Budgetary Educational Institution of Higher Education “Russian University of Medicine” of The Ministry of Health of the Russian Federation, Dolgorukovskaya st., 4, Moscow, 127006, Russian Federation; 6-Kazan State Medical Academy – branch
of the Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia, Butlerova st., 49, Kazan, Republic of Tatarstan, 420012, Russian Federation; 7-Federal State Budgetary Educational Institution of Additional Professional Education “Russian Medical Academy of Continuous Professional Education”, Ministry of Health of Russia, Barrikadnaya st., 2/1, Moscow, 123995, Russian Federation; 8Federal State Budgetary Institution “Scientific Center for Expertise of Medical Devices” of the Ministry of Health of the Russian Federation, Petrovskiy blvd., 8, build. 2, Moscow, 127051, Russian Federation; 9-Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Trubetskaya str., 8, build. 2, Moscow, 119991, Russian Federation; 10Federal State Budgetary Educational Institution of Higher Education “South-Ural State Medical University” of the Ministry
of Healthcare of the Russian Federation, Vorovskogo Street, 64, Chelyabinsk, Chelyabinsk Region, Ural Federal District, 454141, Russian Federation
References
1. Максимов М.Л., Бонцевич Р.А., Бурашникова И.С. и др. Клиническая фармакология и рациональная фармакотерапия для практикующих врачей: учебник. Под ред. М.Л. Максимова. Казань: ИД «МеДДоК», 2021; 948. [Maksimov M.L., Bontsevich R.A., Burashnikova I.S. et al. Clinical pharmacology and rational pharmacotherapy for practicing physicians: textbook. Ed. M.L. Maksimov. Kazan: Publishing House «MeDDoK», 2021; 948 (In Russian).]
2. Poli D., Antonucci E., Ageno W. et al. Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. PLoS One. 2019; 14 (5): e0216831. DOI: 10.1371/journal.pone.0216831.
3. Giustozzi M., Vedovati M.C., Verso M. et al. Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study. Int J Cardiol. 2019; 281: 56–61. DOI: 10.1016/j.ijcard.2019.01.071.
4. Kwon S., Lee S.R., Choi E.K. et al. Non-vitamin K antagonist oral anticoagulants in very elderly East Asians with atrial fibrillation: A nationwide population-based study. Am Heart J. 2020; 229: 81–91. DOI: 10.1016/j.ahj.2020.08.006.
5. Raposeiras-Roubin S., Alonso Rodriguez D., Camacho Freire S.J. et al. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation. J Am Med Dir Assoc. 2020; 21 (3): 367–73.e1. DOI:10.1016/j.jamda.2019.08.033.
6. Van Gelder I.C., Rienstra M., Bunting K.V. et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024; 45 (36): 3314–414. DOI: 10.1093/eurheartj/ehae176.
7. Shah S.J., Singer D.E., Fang M.C. et al. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2019; 12 (11): e006212. DOI: 10.1161/CIRCOUTCOMES.119.006212.
8. Alexander K.P., Brouwer M.A., Mulder H. et al. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019; 208: 123–31. DOI:10.1016/j.ahj.2018.09.017.
9. Jaspers Focks J., Brouwer M.A., Wojdyla D.M. et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016; 353: i2868. DOI:10.1136/bmj.i2868.
10. Gnjidic D., Hilmer S., Blyth F. et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J. Clin. Epidemiol. 2012; 65 (9): 989–95.
11. Piccini J.P., Hellkamp A.S., Washam J.B. et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation. 2016; 133 (4): 352–60. DOI:10.1161/CIRCULATIONAHA.115.018544.
12. Harskamp R.E., Teichert M., Lucassen W.A.M. et al. Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. Cardiovasc Drugs Ther. 2019; 33 (5): 615–23. DOI:10.1007/s10557-019-06907-8.
13. Kim I.S., Kim H.J., Yu H.T. et al. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. J. Cardiol. 2019; 73 (6): 515–21. DOI: 10.1016/j.jjcc.2018.12.018.
14. Man-Son-Hing M., Nichol G., Lau A. et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999; 159: 677–85. DOI: 10.1001/archinte.159.7.677.
15. Rao M.P., Vinereanu D., Wojdyla D.M. et al. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am. J. Med. 2018; 131: 269–75.e2. DOI:10.1016/j.amjmed.2017.10.036.
16. Steffel J., Giugliano R.P., Braunwald E. et al. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J. Am. Coll. Cardiol. 2016; 68 (11): 1169–78. DOI: 10.1016/j.jacc.2016.06.034.
17. Tkacheva O.N., Kotovskaya Y.V., Runikhina N.K. et al. Senile asthenia. Clinical guidelines. Russian J. of Geriatric Medicine. 2020; 1: 11–46. DOI: 10.37586/2686-8636-1-2020-11-46.
18. Kim S., Yoon S., Choi J. et al. Clinical implication of frailty assessment in older patients with atrial fibrillation. Arch Gerontol Geriatr. 2017; 70: 1–7. DOI: 10.1016/j.archger.2016.12.001.
19. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024; 105 (4S): 117–314. DOI: 10.1016/j.kint.2023.10.018.
20. World Health Organization. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. Geneva: World Health Organization, 2024. ISBN 978-92-4-008854-2.
21. Кондрахин А.П., Силина Е.Г., Черняева М.С., Максимов М.Л., Белокопытов А.С., Бабичев А.Н., Смирнова Ю.Е., Мартынова С.А., Шнайдер К.О. Пути увеличения свободы от ПОАК-зависимых осложнений у пациентов пожилого и старческого возраста с полипрагмазией и хронической болезнью почек: молекулярные и генетические аспекты. Молекулярная медицина. 2025; 23 (3): 39–47. DOI:10.29296/24999490-2025-03-05. [Kondrakhin A.P., Silina E.G., Chernyaeva M.S., Maksimov M.L., Belokopytov A.S., Babichev A.N., Smirnova Yu.E., Martynova S.A., Shnaider K.O. Ways to increase freedom from DOAC-dependent complications in elderly patients with polypharmacy and chronic kidney disease: molecular and genetic aspects. Molekulyarnaya meditsina. 2025; 23 (3): 39–47. DOI:10.29296/24999490-2025-03-05. (In Russian).]